Orion Therapeutics awarded NSF Phase II STTR grant to advance lead asset for restenosis, powered by our GENESYS™ targeted delivery platform
We are excited to announce that Orion Therapeutics has been awarded an NSF Phase II STTR grant to advance our lead asset for restenosis, powered by our GENESYS™ targeted delivery platform. This funding will support studies that both move our asset toward IND-enabling development and further validate the GENESYS™ platform as a lipopeptide-enabled lipid nanoparticle […]